Inquiry Basket
Mal-C2-Gly3-EDA-PNU-159682, a drug-linker conjugate for ADC, consists a cleavable ADC linker Mal-C2-Gly3-EDA and a potent ADC cytotoxin PNU-159682.
| Catalog Number | Size | Price | Quantity | |
|---|---|---|---|---|
| BADC-00671 | -- | $-- | Inquiry |
Mal-C2-Gly3-EDA-PNU-159682 is a specialized compound used in the design of targeted drug delivery systems, particularly for cancer treatment. The compound consists of a malonic acid group, a glycine spacer (Gly3), an ethylenediamine (EDA) linker, and the cytotoxic agent PNU-159682, which is conjugated to the biomolecule. PNU-159682 is a potent inhibitor of certain cellular pathways, and its conjugation to the Mal-C2-Gly3-EDA linker allows for its targeted delivery to specific cells. This strategy enhances the drug’s effectiveness by concentrating its activity on the tumor site while minimizing off-target toxicity, a common limitation in traditional chemotherapy. The targeted release of PNU-159682 in cancer cells results in a more precise and efficient treatment.
In addition to its application in targeted cancer therapy, Mal-C2-Gly3-EDA-PNU-159682 is also being studied for its potential in overcoming drug resistance. Many cancer cells develop resistance to conventional chemotherapeutic agents due to the activation of efflux pumps or other mechanisms. By conjugating PNU-159682 to a targeted delivery system using the Mal-C2-Gly3-EDA linker, the drug can bypass these resistance mechanisms. The conjugate is designed to be selectively internalized by cancer cells that express specific receptors, thereby overcoming resistance and ensuring that the full therapeutic potential of PNU-159682 is realized. This approach offers a promising solution to the challenge of multidrug resistance in oncology.
Mal-C2-Gly3-EDA-PNU-159682 is also being explored in combination therapies, where it can be used alongside other therapeutic agents, such as immune checkpoint inhibitors or targeted monoclonal antibodies. The targeted delivery of PNU-159682 can enhance the overall therapeutic response when combined with other treatments. For example, using this conjugate in combination with immune-modulatory agents could help to sensitize cancer cells to immune attack, improving the effectiveness of immunotherapy. This strategy holds promise for enhancing the outcomes of combination therapies, particularly in cancers that are resistant to single-agent treatments or immunotherapies, and for providing a more durable and effective response in patients.
Customer Support
Providing excellent 24/7 customer service and support
Project Management
Offering 100% high-quality services at all stages
Quality Assurance
Ensuring the quality and reliability of products or services
Global Delivery
Ensuring timely delivery of products worldwide
BOC Sciences offers comprehensive services for ADC manufacturing, including antibody modification, linker chemistry, payload conjugation, and formulation development. In particular, our payload-linker customization service offers a convenient and fast raw material channel for many ADC researchers.
BOC Sciences provides one-stop site-specific conjugation services for amino acids, glycans, unnatural amino acids, and short peptide tags. In addition, cysteine conjugation, lysine conjugation, enzymatic conjugation, thio-engineered antibody can also be obtained quickly.
BOC Sciences offers a full range of linkers, including peptide linkers, PEG linkers, click chemistry, PROTAC linkers, non-cleavable linkers, etc. We also provide custom development services for chemically labile linkers and enzymatically cleavable linkers.
